At least 1,000 Covenant Health patients may have been exposed to hepatitis B and C, the organization revealed on Wednesday. Possible exposure was during insulin training sessions in Edmonton between 2013 and 2016. Updated: More than 1,300 Covenant Health patients being treated for diabetes may have been exposed to hepatitis B and C during insulin training sessions, the organization revealed on Wednesday. The health agency has mailed letters to a to
Friday, April 7, 2017 News Recap Canada Effective April 2017, Alberta Health has expanded access to treatments for hepatitis C in line with what the provinces of British Columbia, Ontario, Saskatchewan, and Québec have just done (Alberta expands drug coverage for hepatitis C patients). As Dr. Shafran, who is clearly worried about continued restrictions, says, “The funders have now opened the doors to let us treat people with mild liver disease … if ...
More Albertans suffering from hepatitis C will receive treatment thanks to public funding for new therapies, says Stephen Shafran, a University of Alberta professor of medicine who specializes in the virus. He spoke Wednesday to Postmedia about a game-changing drug and how Alberta can help eradicate hepatitis C. Here’s a condensed, edited version the interview. Q: Alberta Health has made the drug Epclusa available to more patients. The treatment is a p
“Effective April 2017, Alberta Health has agreed to pay for several new therapies for the treatment of hepatitis C, the most important of which is a medicine called Epclusa, which contains two anti-viral drugs,” said Stephen Shafran, a professor of medicine at the University of Alberta. Epclusa, a drug for hep C with a near 100 per cent cure rate, is now going to be covered by Alberta Health. “This should give people hope that they can be cured,” Shafr
Alberta should look at spending $134 million on a hepatitis C screening and treatment program for the province’s baby boomers, most of whom are unaware they carry a heightened risk of infection, two leading medical scientists say. Internationally recognized virologists Dr. Michael Houghton and Dr. Lorne Tyrrell, both based at the University of Alberta, said the costs of such an initiative may seem high, but will be far worse if thousands of undiagnosed di
Less than one percent of Albertans suffer from Hepatitis C, but despite that seemingly low number Dr. Mark Swain with the University of Calgary calls the infection, “prevalent.” That measurement comes in at some 40,000 people. Well, as Dr. Swain tells the Alberta Morning News, a new drug that’s just been approved seeks to help end Hep C. Epclusa is a combination of 2 drugs in one pill, with an enviable success rate. Read more...http://www.630ched.co
HARVONI and SOVALDI ACCESS in CANADA, UPDATES as of March 26 (for original Press Release scroll to page bottom) British Columbia UPDATE on SOVALDI/HARVONI TREATMENT CRITERA and ACCESS as of March 26: BC PharmaCare Listing Criteria: http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/ledipasvir-sofosbuvir.html BC PharmaCare Information for Prescribers – Sofosbuvir-ledipasvir (Harvoni™) for the treatment of chronic hepatitis C infection g